| Objective: Most ovarian cancer patients have been late stage when they went tosee a doctor because of the consealed characteristic, So the patients survival rate of5-years was very low. This brings not only heavily economic burden to society andfamilies, but also severe sorrow to patients and their family members. Currently, thoughthe favorable therapeutic effect have been achieved from chemotherapy which based onplatinum drugs after surgical, part of tumor cells relapsed after a period of time becauseof the cells “escaping” from being killed by chemotherapy. So we must find out themethods of resolving chemotherapy resistance. Our study investigated the expression ofDyrk1B, IKKε, Ki67and ALDH1in ovarian cancer specimens which acceptedcombination chemotherapy basis on the platinum drugs. Meanwhile, we furtherdiscussed drug resistance mechanism and clinical significance about the four indicatorsin the study.Methods: We collected the specimens from14patients with ovarian cancerdisease from2003to2013who were underwent laparotomy or centesis of mass underultrasound guiding when they first came to the hospital. The age of these patients werefrom35to73, with median age of55. All patients were accepted combinedchemotherapy based on platinum drugs after surgical. We divided these patients intotwo groups which one is neoadjuvant chemotherapy group with8patients and the otherone is recurrence group with6patients to do self-control study. The neoadjuvant chemotherapy group was accepted radical operation or maximum limit cytoreductivesurgery after2to3courses of chemotherapy, while the recurrence group was acceptedreoperation after4to8courses of chemotherapy because of the tumor recurrence orpersistently occurred. All specimens from pre-and post-chemotherapy teams were fixedby formalin and embedded by paraffin, which were marked with Dyrk1B、IKKε、Ki67and ALDH1by immunohistochemical SP method. The results were analysised by SPSS19.0through Wilcoxon signed rank test. The statistics was considered significant whenp <0.05.Results：1、The expressions of Dyrk1B, IKKε, Ki67and ALDH1from all of the14specimens before chemotherapy were71.43%、92.86%、92.86%、35.71%, respectively.The expression of these indicators after chemotherapy were respective42.86%、57.14%、50%、14.29%, respectively. The expressive changes of these indicators pre-andpost-chemotherapy were dealed with statistic analysis: the expression of Dyrk1B wereno change（P＞0.05）, but IKKε and Ki67were obviously decreased （P＜0.05）, whileALDH1were no change too（P＞0.05). Further dividing comparision was done:（1）The expressions of Dyrk1B、IKKε、Ki67and ALDH1before chemotherapy on the8patient’s specimens which were accepted in neoadjuvant chemotherapy group were62.50%、62.50%、100%、25%, respectively; and the expressions after chemotherapywere12.50%、37.50%、25%、11.76%, respectively；The expressive changes of theseindicators pre-and post-chemotherapy were dealed with statistic analysis: theexpression of Dyrk1B were no change（P＞0.05）, IKKε and Ki67were decreasedobviously（P＜0.05）, while ALDH1were no change（P＞0.05）.（2）The expressionsof Dyrk1B、IKKε、Ki67and ALDH1before chemotherapy in the6specimens of therecurrence group were83.33%、83.33%、83.33%、50%, respectively；and the expressionafter chemotherapy were50%、83.33%、100%、16.67%, respectively；The changes of4indicators were no statistic significance（P＞0.05）.2、The locations of Dyrk1B expression transfered from peri-nucleus beforechemotherapy to the cytoplasm after chemotherapy were occupied28.57%（4/14）in allspecimens and50%（4/8）in neoadjuvant chemotherapy group. Conclusions：1、The expression level of Dyrk1B was no significant change inevery treatment group pre-and post-chemotherapy, but we found that about50%ofDyrk1B expression in neoadjuvant chemotherapy was transfered from peri-nucleusbefore chemotherapy to the cytoplasm after chemotherapy, suggesting Dyrk1B may beinvolved in the resistance of apoptosis caused by chemotherapy. Furthermore, theexpression of Dyrk1B was almost in cytoplasm in recurrence group, indicating Dyrk1Bfunctions to maintain cell survival and proliferation.2、The expression of IKKε in neoadjuvant chemotherapy group afterchemotherapy were decreased obviously, while it was found to be pesistently expressionin recurrent group, suggesting IKKε may be associated with cell survival and clinicalrecurrence.3、The expression of Ki67was decreased obviously in neoadjuvant chemotherapygroup after chemotherapy, suggesting that chemotherapy inhibited cellular proliferation,while Ki67was persistently expressed in recurrent group with pre-andpost-chemotherapy, indicating the possibility of Ki67was correlated with clinicalrecurrence.4、The expression of ALDH1was no obvious change in the groups of pre-andpost-chemotherapy, so the clinical significance of which need further studied. |
PDF Full Text Request